Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment

• Franklin K. Johnson ,

  Roles Conceptualization, Formal analysis, Methodology, Writing – review & editing

  * E-mail: fjohnson@amicusrx.com

  Affiliation Amicus Therapeutics, Inc., Princeton, New Jersey, United States of America

  https://orcid.org/0000-0002-5426-8171

  ⨯
• Shirley Wu,

  Roles Formal analysis, Writing – review & editing

  Affiliation Biogen, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Ginny Schmith,

  Roles Formal analysis, Writing – review & editing

  Affiliation Schmith PK/PD Consulting LLC, Cocoa Beach, Florida, United States of America

  ⨯
• Hadis Williams,

  Roles Investigation

  Affiliation Amicus Therapeutics, Inc., Princeton, New Jersey, United States of America

  ⨯
• Jasmine Rutecki,

  Roles Investigation

  Affiliation Amicus Therapeutics, Inc., Princeton, New Jersey, United States of America

  ⨯
• Atef Halabi,

  Roles Conceptualization, Investigation, Methodology

  Affiliation CRS Clinical Research Services Kiel GmbH, Kiel, Germany

  ⨯
• Thorsten Feldkamp,

  Roles Conceptualization, Investigation, Methodology

  Affiliation Nephrology Centre Rendsburg-Eckernförde, Rendsburg, Germany

  ⨯
• Anthony Sileno

  Roles Investigation

  Affiliation Amicus Therapeutics, Inc., Princeton, New Jersey, United States of America

  ⨯